NUVB

Nuvation Bio Inc. (NUVB) | Rumor.io

Nuvation Bio

NUVB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,369

Bullish sentiment (50-day avg)80%

Price to earnings ratio-9.35

Market capitalization2B

Earnings per share-0.44

Dividend yield (TTM)—

Revenue (annual)62.9M

Net income (annual)-204.6M

Social

What share of all stock conversation is about NUVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 17

The FDA has approved an updated label for IBTROZI, a treatment for ROS1-positive NSCLC, with a 49.7-month median duration of response for treatment-naive patients.
This approval came four months ahead of the PDUFA date, with no new safety signals, and strengthens Nuvation Bio's commercial story.
The updated label incorporates long-term durability data from the TRUST-I and TRUST-II trials, and is expected to make IBTROZI the most prescribed ROS1 inhibitor for new patients in the US by 2026.

Generated by AI

Sentiment

Of the messages about NUVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	60% -33.94	71.29% -18.58	85.46% +2.33
Bearish	—	40% +33.94	28.71% +18.58	14.54% -2.33

Bullish· Aug 6

The company's first-line patient starts have risen significantly, with 85% of new patients in Q2 2026 being TKI-naïve, indicating a strong commercial validation and potential for continued growth.
Revenue accumulation is a key driver for the company, with patients who started in 2025 remaining on treatment, and new patients added each quarter, leading to a strong potential for revenue growth.
The company's drug, IBTROZI, is becoming the standard of care, with a median duration of response and progression-free survival of approximately 50 months in TKI-naïve patients, and the potential for long-term growth and significant revenue increases.

Bearish· Jun 9

*The author believes that Nuvation Bio Inc. ($NUVB) was manipulated to shake out short-term holders or trigger stop losses, causing its price to drop.
*The company's offer from GSK may have been a factor in its current downtrend, with the author speculating that Sanofi will emerge as a potential buyer instead.
*High short interest in $NUVB, with over 53 million shares shorted, has contributed to the stock's downward movement, with the author suggesting that some funds may have bought shares just before the news broke, leading to retail investors selling at a loss.

Generated by AI

Topics

Of the messages about NUVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.7%	7.26%
Technical Analysis	—	0%	3.77%	1.98%
Analysts	—	0%	20.75%	14.2%
Earnings	—	0%	3.77%	0.52%
Controversies	—	0%	0%	0.02%
Macro	—	0%	0%	76.03%

Analysts· Mar 8

Nuvation Bio Inc. (NUVB) has received upgrades and initiations from multiple analysts, with price targets ranging from $16 to $20.
Analysts at Cowen, BTIG Research, Jefferies, BMO Capital Markets, and Wedbush have initiated coverage on NUVB with ratings of Outperform or Buy, with price targets of $16 to $20.
Analysts believe NUVB's lead program, NUV-422, has significant revenue potential, with one estimate suggesting it could generate over $3 billion by 2028.

Announcements· Jul 20

Nuvation Bio announces updated positive follow-up data from the Phase 2 study of safusidenib in patients with grade 2 IDH1-mutant glioma, with an ORR rate of 52% and a 36-month PFS rate of 79%.
RBC Capital is bullish on Nuvation Bio's safusidenib, citing its competitive profile in IDH1-mutant glioma, and sees a $3B opportunity in the company's brain cancer drug.
Nuvation Bio expands its safusidenib clinical program with two new studies, including a pivotal outside-the-US G307 Phase 3 in grade 2 IDH1-mutant glioma and a US Phase 2 in IDH1-mutant glioma progressed after vorasidenib.

Generated by AI

Community

Of the messages about NUVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	93.33%	82.13%	26.24%
Newcomers	—	6.67%	17.87%	73.76%

Regulars· Sep 17

The FDA has approved a supplemental new drug application for Nuvation Bio's IBTROZI, updating the duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer patients to 49.7 months.
The updated label for IBTROZI shows a median duration of response of over 4 years, with no changes to the safety language, strengthening Nuvation Bio's commercial story and potentially increasing revenue.
The approval comes four months ahead of the scheduled PDUFA date, and the regulars are optimistic about the stock's potential, with some speculating about the possibility of expanding IBTROZI's label for use in treating other cancers.

Newcomers· Jul 20

Nuvation Bio's safusidenib shows a 52% overall response rate (ORR) and a 79% 36-month progression-free survival (PFS) rate in patients with grade 2 IDH1-mutant glioma.
RBC Capital analyst Leonid Timashev believes the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma, and sees a $3 billion opportunity for Nuvation Bio in this area.
Nuvation Bio's expanded clinical program now targets both newly diagnosed grade 2 patients and those who progress after vorasidenib, and the company's stock price rallied over 10% on the news.

Generated by AI

News

Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups

Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemotherapy exposure. IBTROZI efficacy was reported as consistent across different ROS1 fusion partners in patients with advanced ROS1+ non small cell lung cancer. These IBTROZI subgroup findings matter, but investors may wish to weigh them alongside...

13d agoYahoo Finance

Citizens maintains Nuvation Bio stock rating on competitive edge

14d agoInvesting.com

Also Discussed

Investors talking about NUVB also mention

#	Name	Attention
1	Nuvalent, Inc.NUVL	0%0
2	KALV - KalVista Pharmaceuticals, Inc.	——
3	UroGen Pharma Ltd.URGN	0%new
4	Relmada Therapeutics Inc.RLMD	0%0
5	Syndax Pharmaceuticals, Inc.SNDX	0%+0
6	Legend Biotech Corporation ADRLEGN	0%+0
7	Unicycive Therapeutics Inc.UNCY	0%new
8	Grace Therapeutics, Inc.GRCE	0%new
9	SWTX - SpringWorks Therapeutics, Inc.	——
10	Kura Oncology, Inc.KURA	0%+0

Nuvation Bio Inc.

Healthcare
Biotechnology

Nuvation Bio Inc. is a commercial-stage biopharmaceutical company specializing in oncology therapies. The company focuses on cancers with clear molecular drivers and high unmet medical need, emphasizing precision oncology for difficult-to-treat solid tumors. Its current portfolio centers on targeted small-molecule drugs, including taletrectinib, a next-generation ROS1 inhibitor marketed for ROS1-positive non-small cell lung cancer, and safusidenib, a brain-penetrant inhibitor of mutant IDH1 designed for IDH1-driven tumors. Nuvation Bio also advances an innovative drug-drug conjugate program, using proprietary small-molecule constructs to deliver dual therapeutic modalities in a single agent. Operating today as a development-and-commercialization coordinator rather than a large-scale manufacturer, the company creates value by selecting, developing, regulating, and commercializing specialized oncology medicines. Founded in 2018 and headquartered in New York, with additional offices in San Francisco, Boston, and Shanghai, Nuvation Bio plays a growing role in the global market for targeted cancer therapies.

Website

Location

1500 Broadway

New York, NY, 10036

United States

Social

What share of all stock conversation is about NUVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 17

The FDA has approved an updated label for IBTROZI, a treatment for ROS1-positive NSCLC, with a 49.7-month median duration of response for treatment-naive patients.
This approval came four months ahead of the PDUFA date, with no new safety signals, and strengthens Nuvation Bio's commercial story.
The updated label incorporates long-term durability data from the TRUST-I and TRUST-II trials, and is expected to make IBTROZI the most prescribed ROS1 inhibitor for new patients in the US by 2026.

Generated by AI

Sentiment

Of the messages about NUVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	60% -33.94	71.29% -18.58	85.46% +2.33
Bearish	—	40% +33.94	28.71% +18.58	14.54% -2.33

Bullish· Aug 6

The company's first-line patient starts have risen significantly, with 85% of new patients in Q2 2026 being TKI-naïve, indicating a strong commercial validation and potential for continued growth.
Revenue accumulation is a key driver for the company, with patients who started in 2025 remaining on treatment, and new patients added each quarter, leading to a strong potential for revenue growth.
The company's drug, IBTROZI, is becoming the standard of care, with a median duration of response and progression-free survival of approximately 50 months in TKI-naïve patients, and the potential for long-term growth and significant revenue increases.

Bearish· Jun 9

*The author believes that Nuvation Bio Inc. ($NUVB) was manipulated to shake out short-term holders or trigger stop losses, causing its price to drop.
*The company's offer from GSK may have been a factor in its current downtrend, with the author speculating that Sanofi will emerge as a potential buyer instead.
*High short interest in $NUVB, with over 53 million shares shorted, has contributed to the stock's downward movement, with the author suggesting that some funds may have bought shares just before the news broke, leading to retail investors selling at a loss.

Generated by AI

Topics

Of the messages about NUVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.7%	7.26%
Technical Analysis	—	0%	3.77%	1.98%
Analysts	—	0%	20.75%	14.2%
Earnings	—	0%	3.77%	0.52%
Controversies	—	0%	0%	0.02%
Macro	—	0%	0%	76.03%

Analysts· Mar 8

Nuvation Bio Inc. (NUVB) has received upgrades and initiations from multiple analysts, with price targets ranging from $16 to $20.
Analysts at Cowen, BTIG Research, Jefferies, BMO Capital Markets, and Wedbush have initiated coverage on NUVB with ratings of Outperform or Buy, with price targets of $16 to $20.
Analysts believe NUVB's lead program, NUV-422, has significant revenue potential, with one estimate suggesting it could generate over $3 billion by 2028.

Announcements· Jul 20

Nuvation Bio announces updated positive follow-up data from the Phase 2 study of safusidenib in patients with grade 2 IDH1-mutant glioma, with an ORR rate of 52% and a 36-month PFS rate of 79%.
RBC Capital is bullish on Nuvation Bio's safusidenib, citing its competitive profile in IDH1-mutant glioma, and sees a $3B opportunity in the company's brain cancer drug.
Nuvation Bio expands its safusidenib clinical program with two new studies, including a pivotal outside-the-US G307 Phase 3 in grade 2 IDH1-mutant glioma and a US Phase 2 in IDH1-mutant glioma progressed after vorasidenib.

Generated by AI

Community

Of the messages about NUVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	93.33%	82.13%	26.24%
Newcomers	—	6.67%	17.87%	73.76%

Regulars· Sep 17

The FDA has approved a supplemental new drug application for Nuvation Bio's IBTROZI, updating the duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer patients to 49.7 months.
The updated label for IBTROZI shows a median duration of response of over 4 years, with no changes to the safety language, strengthening Nuvation Bio's commercial story and potentially increasing revenue.
The approval comes four months ahead of the scheduled PDUFA date, and the regulars are optimistic about the stock's potential, with some speculating about the possibility of expanding IBTROZI's label for use in treating other cancers.

Newcomers· Jul 20

Nuvation Bio's safusidenib shows a 52% overall response rate (ORR) and a 79% 36-month progression-free survival (PFS) rate in patients with grade 2 IDH1-mutant glioma.
RBC Capital analyst Leonid Timashev believes the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma, and sees a $3 billion opportunity for Nuvation Bio in this area.
Nuvation Bio's expanded clinical program now targets both newly diagnosed grade 2 patients and those who progress after vorasidenib, and the company's stock price rallied over 10% on the news.

Generated by AI

Nuvation Bio

Social

Sep 17

Bullish· Aug 6

Bearish· Jun 9

Analysts· Mar 8

Announcements· Jul 20

Regulars· Sep 17

Newcomers· Jul 20

Why Is Nuvation Bio Stock Gaining Thursday?

Nuvation Bio stock gains on FDA label update for IBTROZI

Why is Nuvation Bio stock surging today?

Nuvation Bio rises on FDA label update for Ibtrozi

Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups

Citizens maintains Nuvation Bio stock rating on competitive edge

Also Discussed

Nuvation Bio Inc.

Company Information

Location

Why Is Nuvation Bio Stock Gaining Thursday?

Nuvation Bio stock gains on FDA label update for IBTROZI

Why is Nuvation Bio stock surging today?

Nuvation Bio rises on FDA label update for Ibtrozi

Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups

Citizens maintains Nuvation Bio stock rating on competitive edge

Also Discussed

Social

Sep 17

Bullish· Aug 6

Bearish· Jun 9

Analysts· Mar 8

Announcements· Jul 20

Regulars· Sep 17

Newcomers· Jul 20